New Thallion
Tax losses conversion is an unique opportunity.
This basically resets the company.
Shareholders can now hope for blue skies.
3 late stage compounds with little clinical risk
4601
232
Shigamabs.
20% stake in Caprion a prometic firm growing at 40% per year. Soon to pay out a dividend and become a cash cow for Thallion.
Caprion gets another contract!:
https://www.genomeweb.com/proteomics/caprion-proteomics-researcher-and-colleagues-land-18m-grant-id-new-type-2-diabet
Sitting 20M, Thallion is a survivor.
Thallion can sustain clinical research until Q2 2011 and is actively reducing cost even further.
GBM results expected late July or August.